|
Autoimmune Lymphoproliferative Syndrome Type 2B
|
0.940 |
Biomarker
|
disease |
BEFREE |
Mixed bone marrow chimeric mice demonstrate that caspase-8 deficiency does not confer preferential expansion of synovial macrophage and dendritic cell populations, nor do caspase-8-deficient synovial populations succumb to RIPK3-mediated necroptotic death.
|
28978351 |
2017 |
|
Autoimmune Lymphoproliferative Syndrome Type 2B
|
0.940 |
Biomarker
|
disease |
BEFREE |
FADD deficiency sensitized more efficiently for TNFR1-mediated necroptosis than caspase-8 deficiency pointing to a caspase-8 independent inhibitory activity of FADD on TNF-induced necroptosis.
|
30741924 |
2019 |
|
Autoimmune Lymphoproliferative Syndrome Type 2B
|
0.940 |
AlteredExpression
|
disease |
BEFREE |
Studies of patients with autoimmune lymphoproliferative syndrome (ALPS) or caspase-8 deficiency state (CEDS) demonstrated the ability of gene expression microarray analyses and small interfering RNAs (siRNA) to establish the physiologically important roles of NRAS, caspase-10, and caspase-8 for normal lymphocyte apoptosis and activation.
|
18818883 |
2009 |
|
Autoimmune Lymphoproliferative Syndrome Type 2B
|
0.940 |
Biomarker
|
disease |
BEFREE |
Thus, caspase-8 deficiency in humans is compatible with normal development and shows that caspase-8 has a postnatal role in immune activation of naive lymphocytes.
|
12353035 |
2002 |
|
Liver carcinoma
|
0.900 |
Biomarker
|
disease |
BEFREE |
Adenovirus-mediated transfection of caspase-8 sensitizes hepatocellular carcinoma to TRAIL- and chemotherapeutic agent-induced cell death.
|
16750275 |
2006 |
|
Liver carcinoma
|
0.900 |
AlteredExpression
|
disease |
BEFREE |
Our data demonstrate that HBV-associated HCC showed a common defect in the expression of Fas, upregulation of FAP and downregulation of downstream molecules such as FADD and FLICE.
|
10025875 |
1998 |
|
Liver carcinoma
|
0.900 |
Biomarker
|
disease |
BEFREE |
Moreover, loss of both Ripk1 and Traf2 in LPC not only resulted in caspase-8 hyperactivation but also impaired NF-κB activation, promoting the spontaneous development of hepatocellular carcinoma.
|
28017612 |
2017 |
|
Liver carcinoma
|
0.900 |
Biomarker
|
disease |
BEFREE |
It suggests that PAK4 as target is a switch between caspase-8 apoptosis and NF-κB survival signals induced by TNF-α in hepatocarcinoma cells.
|
30149917 |
2018 |
|
Liver carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Also, the data suggest that caspase-8 gene mutation might lead to the loss of its cell death function and contribute to the pathogenesis of HCC.
|
15531912 |
2005 |
|
Liver carcinoma
|
0.900 |
Biomarker
|
disease |
BEFREE |
Taken together, our results demonstrated that ASB3 can regulate mitochondrial pathway of apoptosis by controlling caspase-8 mediated cleavage of Beclin1 in HCC.
|
31016535 |
2019 |
|
Liver carcinoma
|
0.900 |
Biomarker
|
disease |
BEFREE |
On the whole, the present study revealed a molecular link between the three‑miRNA signature, comprising miR‑371-5p, miR‑373 and miR‑543, and the negative necroptotic regulator Casp‑8, and presents evidence for its employment as a novel potential diagnostic, prognostic and therapeutic target in HCC.
|
29845207 |
2018 |
|
Liver carcinoma
|
0.900 |
Biomarker
|
disease |
BEFREE |
Here, we mechanistically link caspase-8-dependent apoptosis to HCC development via proliferation- and replication-associated DNA damage.
|
28898696 |
2017 |
|
Liver carcinoma
|
0.900 |
Biomarker
|
disease |
BEFREE |
Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.
|
15105837 |
2004 |
|
Liver carcinoma
|
0.900 |
AlteredExpression
|
disease |
BEFREE |
In this study, we investigated caspase-8 expression in hepatocellular carcinomas (HCCs) using recently described HCC mouse models (c-myc and IgEGF transgenes).
|
16285959 |
2005 |
|
Liver carcinoma
|
0.900 |
Biomarker
|
disease |
BEFREE |
ANP32B knockdown by siRNA altered the expression of apoptosis-related proteins in HCC cell lines and reduced the expression of cleaved forms of caspase 3 and caspase 9, but not that of caspase 8, in HCC cells cultured with the pro-apoptotic agent staurosporine.
|
28486557 |
2017 |
|
Liver carcinoma
|
0.900 |
Biomarker
|
disease |
BEFREE |
We found that the oncolytic adenoviruses Ad·AFP·D55-IL-24 and Ad·AFP·D55-TRAIL express tumor-suppressor gene interleukin-24 (IL-24) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), respectively, significantly suppressed the HCC cell growth in vitro by inducing apoptosis by the caspase-8 and mitochondria-dependent caspase-9 signaling pathways.
|
21979578 |
2012 |
|
Liver carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Caspase-8 is frequently mutated or silenced in several tumors including hepatocellular carcinomas (HCC) thereby potentially contributing to chemoresistance.
|
17922191 |
2007 |
|
Liver carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that the CASP8 -652 6N ins/del polymorphism may play a protective role in the development, progression, and survival of HBV-related HCC among the Chinese Han population.
|
28643196 |
2017 |
|
Liver carcinoma
|
0.900 |
PosttranslationalModification
|
disease |
BEFREE |
Promoter methylation of the caspase 8 and survivin gene was analyzed in 73 primary HCC using methylation-specific polymerase chain reaction.
|
20403046 |
2010 |
|
Liver carcinoma
|
0.900 |
Biomarker
|
disease |
BEFREE |
We investigated the effects of combining wild-type p53 gene transduction by adenoviral infection (Ad-p53) with addition of TRAIL on cell death, expression levels of TRAIL receptors (TRAIL-R1, TRAIL-R2), FLICE inhibitory protein (FLIP) and X-linked inhibitor of apoptosis protein (XIAP) on human hepatocellular carcinoma (HCC) cell lines.
|
15254777 |
2004 |
|
Liver carcinoma
|
0.900 |
AlteredExpression
|
disease |
BEFREE |
This study has investigated whether galangin, a flavonol derived from Alpinia officinarum Hance and used as food additives in southern China, induces apoptosis in hepatocellular carcinoma cells (HCCs) by activation of the caspase-8 and Bid pathway.
|
22575016 |
2012 |
|
Liver carcinoma
|
0.900 |
Biomarker
|
disease |
BEFREE |
Targeted stimulation of the caspase-8 promoter by interferons alpha and gamma, cytotoxic drugs or p53 can substantially sensitize hepatoma cells for apoptosis, whereas hepatocellular carcinoma frequently present an inactive caspase-8 gene promoter.
|
22153863 |
2012 |
|
Liver carcinoma
|
0.900 |
Biomarker
|
disease |
BEFREE |
Ursodeoxycholic acid switches oxaliplatin-induced necrosis to apoptosis by inhibiting reactive oxygen species production and activating p53-caspase 8 pathway in HepG2 hepatocellular carcinoma.
|
19728331 |
2010 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A dose-dependent association was observed between the risk of breast cancer and the genetic risk score, which was an aggregate measure of alleles in seven selected variants, namely FGFR2-rs2981579, TOX3/TNRC9-rs3803662, C6orf97-rs2046210, 8q24-rs13281615, SLC4A7-rs4973768, LSP1-rs38137198, and CASP8-rs10931936.
|
22160591 |
2012 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
For Caucasians, CASP8-652 6N del was associated with reduced breast cancer risk at a borderline level (homozygous: OR=0.94, 95% CI 0.86-1.02, heterozygous: OR=0.96, 95% CI 0.90-1.03, recessive: OR=0.96, 95% CI 0.90-1.03, dominant: OR=0.94, 95% CI 0.88-1.01).
|
24457433 |
2014 |